KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) EBT Margin: 2009-2025

Historic EBT Margin for Biomarin Pharmaceutical (BMRN) over the last 14 years, with Sep 2025 value amounting to -3.39%.

  • Biomarin Pharmaceutical's EBT Margin fell 2142.00% to -3.39% in Q3 2025 from the same period last year, while for Sep 2025 it was 21.95%, marking a year-over-year increase of 773.00%. This contributed to the annual value of 18.98% for FY2024, which is 1119.00% up from last year.
  • According to the latest figures from Q3 2025, Biomarin Pharmaceutical's EBT Margin is -3.39%, which was down 109.40% from 36.09% recorded in Q2 2025.
  • Biomarin Pharmaceutical's EBT Margin's 5-year high stood at 36.09% during Q2 2025, with a 5-year trough of -14.80% in Q4 2021.
  • Moreover, its 3-year median value for EBT Margin was 16.27% (2024), whereas its average is 15.62%.
  • Per our database at Business Quant, Biomarin Pharmaceutical's EBT Margin spiked by 2,106bps in 2022 and then crashed by 2,142bps in 2025.
  • Biomarin Pharmaceutical's EBT Margin (Quarterly) stood at -14.80% in 2021, then skyrocketed by 1,153bps to -3.27% in 2022, then spiked by 626bps to 2.99% in 2023, then soared by 1,971bps to 22.70% in 2024, then tumbled by 2,142bps to -3.39% in 2025.
  • Its last three reported values are -3.39% in Q3 2025, 36.09% for Q2 2025, and 31.95% during Q1 2025.